• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.5-HT1A 受体在治疗精神分裂症和帕金森病中的治疗作用。
CNS Neurosci Ther. 2011 Feb;17(1):58-65. doi: 10.1111/j.1755-5949.2010.00211.x. Epub 2010 Nov 21.
2
New insight into the therapeutic role of 5-HT1A receptors in central nervous system disorders.5-羟色胺1A受体在中枢神经系统疾病治疗作用方面的新见解。
Cent Nerv Syst Agents Med Chem. 2010 Jun 1;10(2):148-57. doi: 10.2174/187152410791196341.
3
5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia.5-羟色胺1A受体依赖性对帕金森病和精神分裂症药物治疗中黑质纹状体多巴胺神经传递的控制
Behav Pharmacol. 2015 Feb;26(1-2):45-58. doi: 10.1097/FBP.0000000000000123.
4
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.阿立哌唑对精神分裂症患者D(2)、5-HT(2)和5-HT(1A)受体占有率的差异效应：一项三重示踪正电子发射断层扫描研究
Am J Psychiatry. 2007 Sep;164(9):1411-7. doi: 10.1176/appi.ajp.2007.06091479.
5
Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.血清素5-HT(1A)受体“偏向性激动剂”在帕金森病和左旋多巴诱导的异动症大鼠模型中的活性
Neuropharmacology. 2015 Jun;93:52-67. doi: 10.1016/j.neuropharm.2015.01.012. Epub 2015 Jan 31.
6
Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation.使用通过激活5-HT(1A)受体引发神经发生的抗精神病药物改善精神分裂症患者的认知功能。
Neurobiol Learn Mem. 2014 Apr;110:72-80. doi: 10.1016/j.nlm.2013.12.015. Epub 2014 Jan 11.
7
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.金刚烷胺和右美沙芬在帕金森病 6-OHDA 大鼠模型中的抗运动障碍机制：NMDA 与 5-HT1A 受体的作用。
Eur J Neurosci. 2012 Nov;36(9):3224-34. doi: 10.1111/j.1460-9568.2012.08243.x. Epub 2012 Aug 3.
8
The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu₂/₃ receptor agonist, LY379268, is 5-HT₁A dependent.代谢型谷氨酸受体2/3（mGlu₂/₃）受体激动剂LY379268对精神分裂症认知症状而非阴性或阳性症状的逆转作用是5-羟色胺1A（5-HT₁A）依赖性的。
Behav Brain Res. 2013 Nov 1;256:298-304. doi: 10.1016/j.bbr.2013.08.007. Epub 2013 Aug 12.
9
Anxiolytic effects of prelimbic 5-HT(1A) receptor activation in the hemiparkinsonian rat.边缘前区5-羟色胺（1A）受体激活对偏侧帕金森病大鼠的抗焦虑作用
Behav Brain Res. 2015 Jan 15;277:211-20. doi: 10.1016/j.bbr.2014.04.053. Epub 2014 Jun 4.
10
Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.联合5-羟色胺（5-HT）1A激动、5-HT（2A）和多巴胺D₂受体拮抗作用可重现非典型抗精神病药物对苯环己哌啶损害的大鼠新奇物体识别的影响。
Behav Brain Res. 2015 May 15;285:165-75. doi: 10.1016/j.bbr.2014.09.040. Epub 2014 Oct 16.

引用本文的文献

1
[F]FDG PET metabolic patterns of the rapid-acting antidepressant effects of NLX-101, a 5-HT receptor biased agonist.[F]5-羟色胺受体偏向性激动剂NLX-101快速起效抗抑郁作用的氟代脱氧葡萄糖正电子发射断层显像代谢模式
Transl Psychiatry. 2025 Sep 1;15(1):336. doi: 10.1038/s41398-025-03572-4.
2
The Role and Mechanisms of G protein-coupled receptors in Parkinson's disease.G蛋白偶联受体在帕金森病中的作用及机制
Neurol Sci. 2025 Jun 11. doi: 10.1007/s10072-025-08260-1.
3
Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases.靶向5-羟色胺是神经退行性疾病的一种潜在治疗策略。
Int J Mol Sci. 2024 Dec 15;25(24):13446. doi: 10.3390/ijms252413446.
4
Extraction, Phytochemical profile, and neuroprotective activity of fruit extract against sodium valproate-induced postnatal autism in BALB/c mice.水果提取物对丙戊酸钠诱导的BALB/c小鼠产后自闭症的提取、植物化学特征及神经保护活性
Heliyon. 2024 Jul 20;10(15):e34992. doi: 10.1016/j.heliyon.2024.e34992. eCollection 2024 Aug 15.
5
Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia.评估NH300094，一种具有认知增强特性的新型多巴胺和5-羟色胺受体调节剂，用于治疗精神分裂症。
Front Pharmacol. 2024 Jan 24;15:1298061. doi: 10.3389/fphar.2024.1298061. eCollection 2024.
6
Atypical antipsychotics attenuate MK801-induced social withdrawal and hyperlocomotion in the RHA rat model of schizophrenia-relevant features.非典型抗精神病药可减轻 MK801 诱导的 RHA 大鼠模型中与精神分裂症相关特征的社交退缩和过度活跃。
Psychopharmacology (Berl). 2023 Sep;240(9):1931-1945. doi: 10.1007/s00213-023-06411-w. Epub 2023 Jul 13.
7
Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research.帕金森病管理中有前景的生物标志物和治疗靶点：最新进展与当代研究
Metab Brain Dis. 2023 Mar;38(3):873-919. doi: 10.1007/s11011-023-01180-z. Epub 2023 Feb 20.
8
Smith-Lemli-Opitz syndrome: A pathophysiological manifestation of the Bloch hypothesis.史密斯-勒米-奥皮茨综合征：布洛赫假说的一种病理生理表现。
Front Mol Biosci. 2023 Jan 12;10:1120373. doi: 10.3389/fmolb.2023.1120373. eCollection 2023.
9
Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism.抗精神病药物所致帕金森症的病理生理机制
Biomedicines. 2022 Aug 18;10(8):2010. doi: 10.3390/biomedicines10082010.
10
Disentangling dyskinesia from parkinsonism in motor structures of patients with schizophrenia.在精神分裂症患者的运动结构中区分异动症和帕金森症。
Brain Commun. 2022 Jul 23;4(4):fcac190. doi: 10.1093/braincomms/fcac190. eCollection 2022.

本文引用的文献

1
Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.新型抗精神病药物鲁拉西酮的药理学特性，其对 5-羟色胺 7（5-HT7）受体和 5-羟色胺 1A（5-HT1A）受体具有强大的活性。
J Pharmacol Exp Ther. 2010 Jul;334(1):171-81. doi: 10.1124/jpet.110.167346. Epub 2010 Apr 19.
2
Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders.皮质和纹状体 5-HT1A 受体在缓解抗精神病药引起的锥体外系疾病中的作用。
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):877-81. doi: 10.1016/j.pnpbp.2010.04.005. Epub 2010 Apr 14.
3
Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.鲁拉西酮治疗急性精神分裂症：一项双盲、安慰剂对照试验。
J Clin Psychiatry. 2009 Jun;70(6):829-36. doi: 10.4088/JCP.08m04905. Epub 2009 Jun 2.
4
The serotonin-1A receptor in anxiety disorders.焦虑症中的5-羟色胺-1A受体。
Biol Psychiatry. 2009 Oct 1;66(7):627-35. doi: 10.1016/j.biopsych.2009.03.012. Epub 2009 May 7.
5
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).抗精神病药物对首发精神分裂症和精神分裂症样障碍的认知影响：一项随机、开放标签的临床试验（EUFEST）
Am J Psychiatry. 2009 Jun;166(6):675-82. doi: 10.1176/appi.ajp.2008.08060806. Epub 2009 Apr 15.
6
Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice.5-HT1A 激动剂抗焦虑药坦度螺酮对小鼠氟哌啶醇诱导的僵住症及前脑 Fos 表达的影响。
J Pharmacol Sci. 2009 Apr;109(4):593-9. doi: 10.1254/jphs.08313fp. Epub 2009 Apr 7.
7
Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.纹状体对5-羟色胺1A受体刺激在左旋多巴治疗的偏侧帕金森病大鼠中所产生效应的作用。
J Neurosci Res. 2009 May 15;87(7):1645-58. doi: 10.1002/jnr.21978.
8
A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory.5-羟色胺（5-HT）1A、5-HT4和5-HT6受体在学习和记忆中的作用。
Trends Pharmacol Sci. 2008 Sep;29(9):482-92. doi: 10.1016/j.tips.2008.07.001.
9
Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.纹状体5-HT1A受体刺激可减轻D1受体诱导的异动症，并改善偏侧帕金森病大鼠的运动。
Neuropharmacology. 2008 Dec;55(8):1321-8. doi: 10.1016/j.neuropharm.2008.08.031. Epub 2008 Sep 10.
10
Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?刺激5-羟色胺（1A）受体能否改善精神分裂症患者的认知功能？
Behav Brain Res. 2008 Dec 16;195(1):98-102. doi: 10.1016/j.bbr.2008.05.016. Epub 2008 May 29.

5-HT1A 受体在治疗精神分裂症和帕金森病中的治疗作用。

Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

机构信息

Laboratory of Pharmacology, Osaka University of Pharmaceutical Sciences, Nasahara, Takatsuki, Osaka, Japan.

出版信息

CNS Neurosci Ther. 2011 Feb;17(1):58-65. doi: 10.1111/j.1755-5949.2010.00211.x. Epub 2010 Nov 21.

DOI:10.1111/j.1755-5949.2010.00211.x
PMID:21091640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6493836/
Abstract

5-HT(1A) receptors have long been implicated in the pathogenesis and treatment of anxiety and depressive disorders. Recently, several lines of studies have revealed new insights into the therapeutic role of 5-HT(1A) receptors in treating schizophrenia and Parkinson's disease. Specifically, 5-HT(1A) receptors seem to be a promising target for alleviating antipsychotic-induced extrapyramidal side effects (EPS) and cognitive/affective disorders in schizophrenia. In the treatment of patients with Parkinson's disease, 5-HT(1A) agonists are expected to improve not only affective symptoms (e.g., anxiety and depression), but also the core parkinsonian symptoms as well as antiparkinsonian agents-induced side effects (e.g., L-DOPA-induced dyskinesia). Here, the therapeutic mechanisms mediated by 5-HT(1A) receptors in schizophrenia and Parkinson's disease are reviewed. This evidence should encourage discovery of new 5-HT(1A) ligands, which can resolve the unmet clinical needs in the current therapy.

摘要

5-HT(1A) 受体长期以来一直与焦虑和抑郁障碍的发病机制和治疗有关。最近，几条研究线揭示了 5-HT(1A)受体在治疗精神分裂症和帕金森病中的治疗作用的新见解。具体来说，5-HT(1A)受体似乎是缓解精神分裂症中抗精神病药引起的锥体外系副作用 (EPS) 和认知/情感障碍的有希望的靶点。在帕金森病患者的治疗中，预计 5-HT(1A)激动剂不仅能改善情感症状（如焦虑和抑郁），还能改善核心帕金森病症状以及抗帕金森病药物引起的副作用（如 L-DOPA 诱导的运动障碍）。在这里，综述了 5-HT(1A)受体在精神分裂症和帕金森病中的治疗机制。这一证据应该鼓励发现新的 5-HT(1A)配体，以解决当前治疗中未满足的临床需求。